reports
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy...
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every time, dramatically raising the probability of success. WARREN, N.J., Sept. 25, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced significant progress in the development of its proprietary PredicTcell™ ...
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persisten...
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today highlights emerging scientific evidence linking persistent viral reservoirs to Long COVID, and emphasizes the potential of its investigational precision T cell therapy, TVGN 489, for the treatment of this debilitating condition which affects an estimated 20 million Americans and represents an area of unmet need. Peer-reviewed studies such as the ones published ...
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s ...
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary Robert F. Kennedy, Jr., and the Trump Administration for convening two Long COVID roundtables focused on patient experiences and research. Long COVID continues to affect millions of Americans; according to Yale Medicine, approximately 20 million adults in the U.S. are living wi...
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum ...
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. The Startup Forum will feature insights from venture capital leaders and early-stage innovators on how they are scaling their companies with Databricks. Mehta ...
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product...
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections. The TVGN 116 cumulative 5-year top-line revenue forecast is es...
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Pro...
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell therapy and the first clinical-stage product from its proprietary ExacTcell™ platform. TVGN-489 is being developed for the treatment of SARS-CoV-2 infection in high-risk vulnerable patients and for Long-COVID in patie...
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipe...
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could be as high as 40,000 patients.Focused on improved prognosis for patients with hematologic malignancies. WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today shared asset value and potential forecast for the...
Tevogen Underscores the Importance of Precision Immunotherapies, Inclu...
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2 WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of complications from the virus. TVGN 489, the Company’s investigational allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte (CTL) immunotherapy is developed using the ExacTcell platform. It is designed to for...
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Discl...
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting rules are not reflected on the Company’s balance sheet, yet represent substantial long-term value. Tevogen will provide detailed information and valuation of these assets in the coming days. Tevogen’s key assets include: Intellectual Property Portfolio – Three wholly owned, granted U.S. patents and twelve p...
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi ...
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today expressed its appreciation to Yale University for recognizing Founder and CEO Dr. Ryan Saadi, MPH ’95, and the Company’s mission of health equity. In recognition from Yale School of Public Health leadership, Dr. Saadi was commended for his “vision to make healthcare more affordable and accessible” and the impact that Tevogen Bio has had on the world. Tevogen’s business ...
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 7...
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC). As reported on June 30, 2025, second quarter institutional ownership of Tevogen common stock increased 24% compared to the reported amount on March 31, 2025; ...
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Heal...
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or the “Company”) (Nasdaq: ), announced today that it has been named in BINJE’s BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio’s Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma. In its recognition, BINJE noted, “Driven by an unrelenting passi...
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in F...
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50...
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial...
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates revenue by end of 2026; Exploring options to address limited tradable float.Building infrastructure, advancing AI, and expanding internal capabilities in a sector with limited growth. WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWI...
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that its Founder and CEO, Dr. Ryan Saadi, has donated 10,000 of his personal shares of common stock to the Warren Township Honorary Policemen’s Benevolent Association (P.B.A.) Local 235. The Warren Township P.B.A. Local 235 is a non-profit organization dedicated to supporting local schools, community events, and charitable causes. The organization contributes to the D.A.R.E. and Explorer programs, prov...
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that Founder and CEO of Tevogen, Dr. Ryan Saadi, donated 10,000 of his personal shares of common stock to the Opportunity Project, a Millburn, N.J.–based nonprofit dedicated to empowering individuals with brain injuries through its innovative Clubhouse model. Founded in 1993, Opportunity Project has served more than 600 individuals and their families, providing programs that foster independence, self‑es...
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fu...
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or the “Company”) (Nasdaq: ), today issued the following statement from Ryan Saadi, M.D., M.P.H., Founder and CEO. “Tevogen is an asset-rich enterprise, and we plan on sharing a comprehensive inventory of Tevogen’s wholly owned internally developed assets and their standard methodology valuation. These intangible assets are not reflected in financial reports due to US GAAP accounting rules, but they do underscore the magnitude of what we have b...
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsof...
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development.Tevogen.AI to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams. WARREN, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Ho...
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value E...
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or the “Company) (Nasdaq: ), reiterates investor confidence and estimated asset value over $10 billion. In October 2024, HMP Partners and The Patel Family LLP, investors in innovative healthcare ventures, congratulated Tevogen Bio and Dr. Ryan Saadi for their efforts to alleviate health inequality through breakthrough life-saving medical innovations. Hema Patel, Managing Partner of HMP Partners and The Patel Family LLP, remarked, “We are i...
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast...
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five years. WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmod...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.